Skip to main content

Table 2 Cohort characteristics at baseline

From: Long-term outcomes in patients with type 2 diabetes receiving glimepiride combined with liraglutide or rosiglitazone

Characteristic

Baseline value

SD

Reference

Demographics

   

Mean age (years)

56.1

9.8

25

Duration of diabetes (years)

7.9

5.4

25

Proportion male (%)

49.4

 

25

Risk factors

   

HbA1c (%)

8.4

0.9

25

SBP (mmHg)

132.1

15.4

25

BMI (kg/m2)

29.9

5.1

25

Total cholesterol (mg/dl)

196.15

42.3

25

LDL (mg/dl)

130.76

38.46

25

HDL (mg/dl)

50

11.53

25

Triglycerides (mg/dl)

190.9

145.5

25

Ethnic group (%)

   

   White

64.5

 

Novo Nordisk, data on file

   Black

2.9

 

Novo Nordisk, data on file

   Asian

32.5

 

Novo Nordisk, data on file

Cardiovascular disease

   

Stroke (%)

0.9

 

Novo Nordisk, data on file

Angina pectoris (%)

1.0

 

Novo Nordisk, data on file

MI (%)

1.4

 

Novo Nordisk, data on file

CHF (%)

0.1

 

Novo Nordisk, data on file

Atrial fibrillation (%)

1.5

 

Novo Nordisk, data on file

LVH by ECG (%)

0.7

 

Novo Nordisk, data on file

PVD (%)

0.8

 

Novo Nordisk, data on file

Renal disease

   

Microalbuminuria (%)

1.1

 

Novo Nordisk, data on file

Gross proteinuria (%)

0.1

 

Novo Nordisk, data on file

End-stage renal disease (%)

0.1

 

Novo Nordisk, data on file

Retinopathy

   

Background diabetic retinopathy (%)

14.9

 

Novo Nordisk, data on file

Proliferative diabetic retinopathy (%)

0.1

 

Novo Nordisk, data on file

Other complications

   

Peripheral neuropathy (%)

20.0

 

Novo Nordisk, data on file

Foot ulcer (%)

0.1

 

Novo Nordisk, data on file

Amputation (%)

0.3

 

Novo Nordisk, data on file

Cataract (%)

5.6

 

Novo Nordisk, data on file

Macular edema (%)

0.2

 

Novo Nordisk, data on file

Severe vision loss (%)

0.1

 

Novo Nordisk, data on file

Patient management

   

ACE-I/ARBs (%)

48.7

 

18

Statins (%)

28.2

 

18

Aspirin (%)

43.9

 

18

Screened for retinopathy (%)

67.7

 

39

Screened for renal disease (%)

55

 

40

Screened for foot disease (%)

68.3

 

39

  1. ARB, angiotensin receptor blocker; ACE-I angiotensin-converting enzyme inhibitor; BMI, body mass index; CHF, congestive heart failure; HDL, high-density lipoprotein; LDL, low-density lipoprotein; LVH by ECG, left ventricular hypertrophy confirmed by electrocardiogram; MI, myocardial infarction; PVD, peripheral vascular disease; SBP, systolic blood pressure.